Jade Biosciences, Inc.: 5%+ holders

As of November 10, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Jade Biosciences, Inc. The largest reported stake is Fairmount Funds Management LLC's, at 19.99%. 23 filings are on record since July 17, 2025 (Schedule 13D/A, June 9, 2026).

Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company ↓

Sell to companies like Jade Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-28 · Reporting person: Franklin Templeton, Inc. · Sole voting: 3,706,532 · Shared voting: 0 · Sole dispositive: 3,807,236 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-28
• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 3,231,840 · Shared voting: 0 · Sole dispositive: 3,323,301 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 5,145,330 · Sole dispositive: 0 · Shared dispositive: 5,145,330 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Bellevue Group AG · Sole voting: 0 · Shared voting: 3,057,996 · Sole dispositive: 0 · Shared dispositive: 3,057,996 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-07-17 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 3,106,793 · Shared voting: 0 · Sole dispositive: 3,106,793 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-17

Jade Biosciences, Inc. has 23 Schedule 13D or 13G filings on record since 2025-07-17. 8 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Jade Biosciences, Inc. and the warning signs.

See Jade Biosciences, Inc.'s free Snapshot Watch Jade Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Jade Biosciences, Inc. and the records around it.

Jade Biosciences, Inc. elsewhere on the record

• Leadership changes Jun 2026
• Who owns it

Companies that share a holder

• Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Vera Therapeutics, Inc. (Mar 2026)
• Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Celldex Therapeutics, Inc. (May 2026), Viridian Therapeutics, Inc. (May 2026)
• Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)

Want the whole picture on Jade Biosciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Jade Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Jade Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   25 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Jade Biosciences, Inc. by CUSIP 008064206 and gives its principal executive office as 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (SCHEDULE 13G, 2026-10-28).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14

See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 60,845,967 shares of Common Stock outstanding as of June 5, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on June 4, 2026 and its Press Release issued on June 5, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G, 2026-07-17

Purpose of Transaction (Item 4)

Sofinnova Venture Partners X, L.P. ("SVP X")

The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-03-05

Timeline

Swipe the table sideways to see every column.

Questions about who owns Jade Biosciences, Inc.

Who owns Jade Biosciences, Inc.?

On this page, 8 holders' latest ownership filings report 5% or more of Jade Biosciences, Inc.: Fairmount Funds Management LLC (19.99%, Schedule 13D/A, filed 2026-06-09), JANUS HENDERSON GROUP Ltd. (10.6%, Schedule 13G/A, filed 2026-07-08), Venrock Healthcare Capital Partners III, L.P. (8.3%, Schedule 13G/A, filed 2026-08-14), RA Capital Management, L.P. (7%, Schedule 13G, filed 2025-10-16) and Franklin Templeton, Inc. (6%, Schedule 13G, filed 2026-10-28); 3 more are listed above.

Who are the largest shareholders of Jade Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Jade Biosciences, Inc. on this page are Fairmount Funds Management LLC (19.99%), JANUS HENDERSON GROUP Ltd. (10.6%) and Venrock Healthcare Capital Partners III, L.P. (8.3%).

When did Fairmount Funds Management LLC buy into Jade Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fairmount Funds Management LLC on this page is the Schedule 13D/A, filed 2025-10-08, reporting 19.99%; its latest, Schedule 13D/A filed 2026-06-09, reports 19.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 23 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Jade Biosciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Jade Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Jade Biosciences, Inc. is mentioned again
• Find former Jade Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes